All In Biotech

Investigational drug · Phase 3

SHR-1918

Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Homozygous Familial Hypercholesterolemia, Hyperlipidemia, Hypercholesterolemia.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

7

4 still active

All registered trials

10

Any phase or sponsor naming "SHR-1918"

First trial start

2023

Nov 24, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "SHR-1918", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Homozygous Familial Hypercholesterolemia
  • Hyperlipidemia
  • Hypercholesterolemia
  • Hypertriglyceridemia
  • Hyperlipidemic

Approved drugs for the same conditions: High cholesterol · High triglycerides · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "SHR-1918" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 8 on PubMed

Also in development for Homozygous Familial Hypercholesterolemia

  • ZodasiranAROANG3, VSA003Phase 33 trials

    Arrowhead Pharmaceuticals · Homozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia (HoFH)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.